Company / Cash & Equivalents
Abbott Laboratories Cash & Equivalents History
FY2016-FY2025 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest Cash & Equivalents
$8.5B
FY2025
5-year range
$6.9B / $9.9B
FY2021-FY2025
Trend
+11.9%
vs FY2024
Sector context
#5 of 148
Health Care
What the data says
Among 148 Health Care companies, Abbott Laboratories is in the top 3% for cash & equivalents. Cash & Equivalents has fluctuated over the past 10 years, ranging from $3.8B in FY2018 to $9.9B in FY2022.
Based on SEC 10-K filings.
$8.5B in FY2025 with a 5-year CAGR of +4.5%. Top quartile in the Health Care sector.
Improved from $6.9B to $8.5B over the past 2 years.
Health Care sector context is included.
Cash & Equivalents over time
Growth rates
- 3-Year CAGR
- -4.8%
- 5-Year CAGR
- +4.5%
- 10-Year CAGR
- -
Sector benchmark
Top 3% in Health CareTop 3% of 148This company $8.5B Sector average $1.2B
▼
+624.2% above sector average
Key checks
Key Insights
- 5-year CAGR of +4.5%, indicating consistent growth.
- In FY2025, cash & equivalents increased 11.9% year-over-year.
- Ranks #5 out of 148 companies in the Health Care sector.
- Peak cash & equivalents was recorded in FY2022.
Company context
Key Data Points
- Strong profit margin: 31.9%
- High earnings quality (cash-backed earnings)
- Strong return on equity: 27.4%
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | Cash & EquivalentsValue | YoY GrowthYoY |
|---|---|---|
| FY2025 | $8.5B | +11.9% |
| FY2024 | $7.6B | +10.4% |
| FY2023 | $6.9B | -30.2% |
| FY2022 | $9.9B | +0.8% |
| FY2021 | $9.8B | +43.3% |
| FY2020 | $6.8B | +77.2% |
| FY2019 | $3.9B | +0.4% |
| FY2018 | $3.8B | -59.1% |
| FY2017 | $9.4B | +131.5% |
| FY2016 | $4.1B | +16.9% |
As of FY2025 · SEC 10-K · Updated Jun 30, 2026